Saikosaponin b1 Attenuates Liver Fibrosis by Blocking STAT3/Gli1 Interaction and Inducing Gli1 Degradation

Abstract

Saikosaponin b1 (Ssb1), a natural oleanane-type triterpenoid saponin, exhibits antifibrosis activity by inhibiting the activation of hepatic stellate cells (HSCs), but the specific underlying molecular mechanisms are unknown. Here, it is found that Ssb1 could directly bind with the signal transducer and activator of transcription 3 (STAT3) and effectively inhibit the activation of HSCs. Proteomic techniques and molecular simulation revealed that Ssb1 is mainly bound to the S319 residues of STAT3 in the coiled-coil domain. Further studies indicated that Ssb1 binding with STAT3 inhibited its transcriptional activity, and regulated glioma-associated oncogene-1 (Gli1) expression in the Hedgehog signaling pathway. Besides, Ssb1 binding blocked interaction between STAT3 and Gli1, which promoted degradation of Gli1 protein by suppressor of fused homolog (SUFU) and the ubiquitin-proteasome system. The loss function of Gli1 led to decreased expression of Bcl2 and promoted the apoptosis of activated HSCs. Moreover, STAT3 ablation abolished the Ssb1-mediated antifibrotic effects. These findings show that STAT3 plays a vital role in Ssb1 treatment of liver fibrosis, and Ssb1 as a STAT3 inhibitor might be a promising therapeutic candidate for the treatment of hepatic fibrosis.

Keywords

liver fibrosis / Ssb1 binding site of STAT3 / STAT3/Gli1 interaction

References

[1] G. O. Elpek, “Cellular and Molecular Mechanisms in the Pathogenesis of Liver Fibrosis: An Update,” World Journal of Gastroenterology20 (2014): 7260-7276.

[2] T. Tsuchida and S. L. Friedman, “Mechanisms of Hepatic Stellate Cell Activation,” Nature Reviews Gastroenterology and Hepatology14 (2017): 397-411.

[3] D. Y. Zhang and S. L. Friedman, “Fibrosis-Dependent Mechanisms of Hepatocarcinogenesis,” Hepatology56 (2012): 769-775.

[4] R. Weiskirchen, S. Weiskirchen, and F. Tacke, “Organ and Tissue Fibrosis: Molecular Signals, Cellular Mechanisms and Translational Implications,” Molecular Aspects of Medicine65 (2019): 2-15.

[5] V. Krizhanovsky, M. Yon, R. A. Dickins, et al., “Senescence of Activated Stellate Cells Limits Liver Fibrosis,” Cell134 (2008): 657-667.

[6] E. Albanis and S. L. Friedman, “Antifibrotic Agents for Liver Disease,” American Journal of Transplantation6 (2006): 12-19.

[7] S. L. Friedman, “Evolving Challenges in Hepatic Fibrosis,” Nature Reviews Gastroenterology & Hepatology7 (2010): 425-436.

[8] N. Arroyo, L. Villamayor, I. Díaz, et al., “GATA4 Induces Liver Fibrosis Regression by Deactivating Hepatic Stellate Cells,” JCI Insight6 (2021): e150059.

[9] P. Manka, A. Zeller, and W. K. Syn, “Fibrosis in Chronic Liver Disease: An Update on Diagnostic and Treatment Modalities,” Drugs79 (2019): 903-927.

[10] Y.-X. Wang, Y. Du, X.-F. Liu, et al., “A Hepatoprotection Study of Radix Bupleuri on Acetaminophen-Induced Liver Injury Based on CYP450 Inhibition,” Chinese Journal of Natural Medicines17 (2019): 517-524.

[11] T. Lei, S. Chen, K. Wang, et al., “Characterization and Discrimination of Raw and Vinegar-Baked Bupleuri Radix Based on UHPLC-Q-TOF-MS Coupled With Multivariate Statistical Analysis,” Biomedical Chromatography32 (2018): e4044, https://doi.org/10.1002/bmc.4044.

[12] M. Gao, X. Huo, L. Lu, M. Liu, and G. Zhang, “Analysis of Codon Usage Patterns in Bupleurum Falcatum Chloroplast Genome,” Chinese Herbal Medicines15 (2023): 284-290.

[13] S. Wang, Y. Zhang, Q. Zhang, et al., “Content Decline of SERCA Inhibitors Saikosaponin A and D Attenuates Cardiotoxicity and Hepatotoxicity of Vinegar-Baked Radix Bupleuri,” Environmental Toxicology and Pharmacology52 (2017): 129-137.

[14] J. Luo, J. Wang, J. Yang, et al., “Saikosaponin B1 and Saikosaponin D Inhibit Tumor Growth in Medulloblastoma Allograft Mice via Inhibiting the Hedgehog Signaling Pathway,” Journal of Natural Medicines76 (2022): 584-593.

[15] F. Yang, X. Dong, X. Yin, W. Wang, L. You, and J. Ni, “Radix Bupleuri: A Review of Traditional Uses, Botany, Phytochemistry, Pharmacology, and Toxicology,” BioMed Research International2017 (2017): 7597596.

[16] R. Wang, J. Kong, D. Wang, L. L. Lien, and E. J. Lien, “A Survey of Chinese Herbal Ingredients With Liver Protection Activities,” Chinese Medicine2 (2007): 5.

[17] M. Peng, M. Shao, H. Dong, et al., “Nanodrug Rescues Liver Fibrosis via Synergistic Therapy With H2O2 Depletion and Saikosaponin b1 Sustained Release,” Communications Biology6 (2023): 184.

[18] D. Chakraborty, B. Sumova, T. Mallano, et al., “Activation of STAT3 Integrates Common Profibrotic Pathways to Promote Fibroblast Activation and Tissue Fibrosis,” Nature Communications8 (2017): 1130.

[19] X. Zhang, Y. Sun, R. Pireddu, et al., “A Novel Inhibitor of STAT3 Homodimerization Selectively Suppresses STAT3 Activity and Malignant Transformation,” Cancer Research73 (2013): 1922-1933.

[20] V. Carloni, R. G. Romanelli, M. Pinzani, G. Laffi, and P. Gentilini, “Expression and Function of Integrin Receptors for Collagen and Laminin in Cultured Human Hepatic Stellate Cells,” Gastroenterology110 (1996): 1127-1136.

[21] Z. Hu, Y. Han, Y. Liu, et al., “CREBZF as a Key Regulator of STAT3 Pathway in the Control of Liver Regeneration in Mice,” Hepatology71 (2020): 1421-1436.

[22] T.-H. Su, C.-W. Shiau, P. Jao, et al., “Sorafenib and Its Derivative SC-1 Exhibit Antifibrotic Effects Through Signal Transducer and Activator of Transcription 3 Inhibition,” Proceedings of the National Academy of Sciences of the United States of America112 (2015): 7243-7248.

[23] S. Ye, W. Luo, Z. A. Khan, et al., “Celastrol Attenuates Angiotensin II-Induced Cardiac Remodeling by Targeting STAT3,” Circulation Research126 (2020): 1007-1023.

[24] L. X. Liao, X. M. Song, L. C. Wang, et al. Proceedings of the National Academy of Sciences of the United States of America114 (2017): E5986-E5994.

[25] Y. Liu, Q. Guo, H. Yang, et al., “Allosteric Regulation of IGF2BP1 as a Novel Strategy for the Activation of Tumor Immune Microenvironment,” ACS Central Science8 (2022): 1102-1115.

[26] Q. Lu, Y. Zhang, J. Hellner, et al., “Proteome-Wide Cellular Thermal Shift Assay Reveals Unexpected Cross-talk Between Brassinosteroid and Auxin Signaling,” Proceedings of the National Academy of Sciences of the United States of America119 (2022): e2118220119.

[27] G. Garcia-Tsao, S. Friedman, J. Iredale, and M. Pinzani, “Now There Are Many (stages) Where Before There Was One,” Hepatology51 (2010): 1445-1449.

[28] X. Guan, J. Yang, W. Wang, et al., “Dual Inhibition of MYC and SLC39A10 by a Novel Natural Product STAT3 Inhibitor Derived From Chaetomium Globosum Suppresses Tumor Growth and Metastasis in Gastric Cancer,” Pharmacological Research189 (2023): 106703.

[29] J. Wang, Z. Huang, L. Ji, et al., “SHF Acts as a Novel Tumor Suppressor in Glioblastoma Multiforme by Disrupting STAT3 Dimerization,” Advanced Science9 (2022): e2200169.

[30] X. Zhu, S. Ye, D. Yu, et al., “Physalin B Attenuates Liver Fibrosis via Suppressing LAP2α-HDAC1-Mediated Deacetylation of the Transcription Factor GLI1 and Hepatic Stellate Cell Activation,” British Journal of Pharmacology178 (2021): 3428-3447.

[31] X. Gai, K. Tu, C. Li, Z. Lu, L. R. Roberts, and X. Zheng, “Histone Acetyltransferase PCAF Accelerates Apoptosis by Repressing a GLI1/BCL2/BAX Axis in Hepatocellular Carcinoma,” Cell Death & Disease6 (2015): e1712-e1712.

[32] S. R. Sirkisoon, R. L. Carpenter, T. Rimkus, et al., “Interaction Between STAT3 and GLI1/tGLI1 Oncogenic Transcription Factors Promotes the Aggressiveness of Triple-Negative Breast Cancers and HER2-Enriched Breast Cancer,” Oncogene37 (2018): 2502-2514.

[33] T. Manshouri, I. Veletic, Y. Zhang, et al., “STAT3-Induced Gli1 Promotes the Differentiation and Maturation of Myelofibrosis Fibrocytes,” Blood134 (2019): 2961-2961.

[34] T. Manshouri, I. Veletic, P. Li, et al., “GLI1 Activates Pro-Fibrotic Pathways in Myelofibrosis Fibrocytes,” Cell Death & Disease13 (2022): 481.

[35] R. M. Carr, P. A. Romecin Duran, E. J. Tolosa, et al., “The Extracellular Sulfatase SULF2 Promotes Liver Tumorigenesis by Stimulating Assembly of a Promoter-Looping GLI1-STAT3 Transcriptional Complex,” Journal of Biological Chemistry295 (2020): 2698-2712.

[36] N. K. Agarwal, C. H. Kim, K. Kunkalla, et al., “Active IKKβ Promotes the Stability of GLI1 Oncogene in Diffuse Large B-Cell Lymphoma,” Blood127 (2016): 605-615.

[37] W. Wang, T. Yan, W. Guo, et al., “Constitutive GLI1 Expression in Chondrosarcoma is Regulated by Major Vault Protein via mTOR/S6K1 Signaling Cascade,” Cell Death and Differentiation28 (2021): 2221-2237.

[38] S. Sharma, D. Le Guillou, and J. Y. Chen, “Cellular Stress in the Pathogenesis of Nonalcoholic Steatohepatitis and Liver Fibrosis,” Nature Reviews Gastroenterology & Hepatology20 (2023): 662-678.

[39] J.-C. Martinou and R. J. Youle, “Mitochondria in Apoptosis: Bcl-2 Family Members and Mitochondrial Dynamics,” Developmental Cell21 (2011): 92-101.

[40] L. C. Santos, R. Vogel, J. E. Chipuk, M. R. Birtwistle, G. Stolovitzky, and P. Meyer, “Mitochondrial Origins of Fractional Control in Regulated Cell Death,” Nature Communications10 (2019): 1313.

[41] D. Kaloni, S. T. Diepstraten, A. Strasser, and G. L. Kelly, “BCL-2 Protein Family: Attractive Targets for Cancer Therapy,” Apoptosis28 (2022): 20-38.

[42] Z. Li, J. Jo, J. M. Jia, et al., “Caspase-3 Activation via Mitochondria is Required for Long-Term Depression and AMPA Receptor Internalization,” Cell141 (2010): 859-871.

[43] V. Hernandez-Gea and S. L. Friedman, “Pathogenesis of Liver Fibrosis,” Annual Review of Pathology6 (2011): 425-456.

[44] H. Yu, D. Pardoll, and R. Jove, “STATs in Cancer Inflammation and Immunity: A Leading Role for STAT3,” Nature Reviews Cancer9 (2009): 798-809.

[45] A. K. Ajay, L. Zhao, S. Vig, et al., “Deletion of STAT3 From Foxd1 Cell Population Protects Mice From Kidney Fibrosis by Inhibiting Pericytes Trans-Differentiation and Migration,” Cell Reports38 (2022): 110473.

[46] Y. Liu, H. Liu, C. Meyer, et al., “Transforming Growth Factor-β (TGF-β)-Mediated Connective Tissue Growth Factor (CTGF) Expression in Hepatic Stellate Cells Requires Stat3 Signaling Activation,” Journal of Biological Chemistry288 (2013): 30708-30719.

[47] X. Kong, D. Feng, H. Wang, et al., “Interleukin-22 Induces Hepatic Stellate Cell Senescence and Restricts Liver Fibrosis in Mice,” Hepatology56 (2012): 1150-1159.

[48] N. Odagiri, T. Matsubara, M. Higuchi, et al., “Involvement of ERK1/2 Activation in the Gene Expression of Senescence-associated Secretory Factors in Human Hepatic Stellate Cells,” Molecular and Cellular Biochemistry455 (2018): 7-19.

[49] L. Wang, Y. Feng, X. Xie, et al., “Neuropilin-1 Aggravates Liver Cirrhosis by Promoting Angiogenesis via VEGFR2-Dependent PI3K/Akt Pathway in Hepatic Sinusoidal Endothelial Cells,” EBioMedicine43 (2019): 525-536.

[50] J. Dong, X. D. Cheng, W. D. Zhang, and J. J. Qin, “Recent Update on Development of Small-Molecule STAT3 Inhibitors for Cancer Therapy: From Phosphorylation Inhibition to Protein Degradation,” Journal of Medicinal Chemistry64 (2021): 8884-8915.

[51] Y. Wang, S. Wu, X. Zhu, et al., “LncRNA-Encoded Polypeptide ASRPS Inhibits Triple-Negative Breast Cancer Angiogenesis,” Journal of Experimental Medicine217 (2020): e20190950.

[52] J. Ma, T. Zhang, V. Novotny-Diermayr, A. L. C. Tan, and X. Cao, “A Novel Sequence in the Coiled-Coil Domain of Stat3 Essential for Its Nuclear Translocation,” Journal of Biological Chemistry278 (2003): 29252-29260.

RIGHTS & PERMISSIONS

2025 The Author(s). Exploration published by Henan University and John Wiley & Sons Australia, Ltd.